# Cognition Therapeutics

Cognition Therapeutics is an Asset Manager based in Pittsburgh, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Pittsburgh, United States
- **Region:** North America
- **Address:** Pittsburgh, PA, United States
- **Founded:** 2007
- **Assets under management:** Undisclosed
- **Website:** cogrx.com

## Regulatory record

- **Reports private funds:** No

## About

Cognition Therapeutics was founded in 2007, based on research into oligomer-pathway biology conducted by its scientific founders out of the University of Pittsburgh. The company operates as a publicly traded clinical-stage biopharmaceutical firm, not a family office, and its capital comes from equity markets and grant funding rather than a single family's wealth pool. Lisa Ricciardi took the CEO post in 2023, bringing a commercial-stage pedigree from roles at Turning Point Therapeutics and Array BioPharma. The company's therapeutic focus rests entirely on sigma-2 receptor modulation. Its lead drug candidate, CT1812, is an orally delivered small molecule designed to displace toxic amyloid-beta oligomers from synaptic receptor sites. Both trials inform an upcoming Phase 2/3 program that Cognition plans to advance with a strategic partner. The company raised roughly $45 million in its 2021 IPO and subsequently drew grant support from the National Institute on Aging for more than $80 million in total non-dilutive funding. Team size is not publicly fixed but the firm operates a lean clinical-development model, outsourcing manufacturing and large-trial execution. There are no known adjacent vehicles or philanthropic arms. As of early 2025, the board added neuroscience drug-development veteran Anthony Caggiano, signaling a build toward late-stage regulatory capability. Structurally, Cognition Therapeutics is an unusual bet among neurodegenerative drug companies: it bypasses the now-crowded anti-amyloid antibody space entirely, targeting a receptor complex that sits upstream of multiple misfolded protein cascades.

## Sectors

- Digital Health
- Biotechnology

## People

- Lisa Ricciardi — President and Chief Executive Officer

## Questions

### What is Cognition Therapeutics' lead drug candidate and how does it work?

CT1812 is an oral small molecule that binds the sigma-2 receptor complex on neuronal synapses. The proposed mechanism is displacement of toxic amyloid-beta oligomers from synaptic binding sites, thereby restoring normal signaling and slowing neurodegeneration. Two Phase 2 trials have reported results in Alzheimer's disease and dementia with Lewy bodies.

### What is the current clinical-stage status of CT1812?

CT1812 has completed the SHINE Phase 2 trial in mild-to-moderate Alzheimer's disease and the SHIMMER Phase 2 trial in dementia with Lewy bodies. Neither trial met its primary endpoint in the full population, but SHINE showed a statistically significant cognitive benefit in a subgroup with lower baseline plasma p-tau217 levels. The company is planning a confirmatory Phase 2/3 program.

### Who runs investment or capital-allocation decisions at Cognition?

Capital allocation is decided by the CEO, Lisa Ricciardi, alongside the board of directors. As a publicly traded company, material uses of capital — including clinical-trial scale-up and partnership structures — are subject to board oversight and market disclosure obligations.

### How is Cognition Therapeutics funded if it has no disclosed AUM?

The company is funded through a combination of equity raises, including its 2021 initial public offering, and non-dilutive grant awards. The National Institute on Aging has provided more than $80 million in grant support. The firm does not manage third-party capital in a traditional asset-management sense and therefore does not report AUM.

## Related profiles

- [Western Asset Investment Grade Income Fund](https://altss.com/profile/western-asset-investment-grade-income-fund-inc)
- [Riverview Bancorp](https://altss.com/profile/riverview-bancorp-inc)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/cognition-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology